Cargando…
Biomaterial-Mediated Factor Delivery for Spinal Cord Injury Treatment
Spinal cord injury (SCI) is an injurious process that begins with immediate physical damage to the spinal cord and associated tissues during an acute traumatic event. However, the tissue damage expands in both intensity and volume in the subsequent subacute phase. At this stage, numerous events exac...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313204/ https://www.ncbi.nlm.nih.gov/pubmed/35884981 http://dx.doi.org/10.3390/biomedicines10071673 |
_version_ | 1784754022259884032 |
---|---|
author | Pinelli, Filippo Pizzetti, Fabio Veneruso, Valeria Petillo, Emilia Raghunath, Michael Perale, Giuseppe Veglianese, Pietro Rossi, Filippo |
author_facet | Pinelli, Filippo Pizzetti, Fabio Veneruso, Valeria Petillo, Emilia Raghunath, Michael Perale, Giuseppe Veglianese, Pietro Rossi, Filippo |
author_sort | Pinelli, Filippo |
collection | PubMed |
description | Spinal cord injury (SCI) is an injurious process that begins with immediate physical damage to the spinal cord and associated tissues during an acute traumatic event. However, the tissue damage expands in both intensity and volume in the subsequent subacute phase. At this stage, numerous events exacerbate the pathological condition, and therein lies the main cause of post-traumatic neural degeneration, which then ends with the chronic phase. In recent years, therapeutic interventions addressing different neurodegenerative mechanisms have been proposed, but have met with limited success when translated into clinical settings. The underlying reasons for this are that the pathogenesis of SCI is a continued multifactorial disease, and the treatment of only one factor is not sufficient to curb neural degeneration and resulting paralysis. Recent advances have led to the development of biomaterials aiming to promote in situ combinatorial strategies using drugs/biomolecules to achieve a maximized multitarget approach. This review provides an overview of single and combinatorial regenerative-factor-based treatments as well as potential delivery options to treat SCIs. |
format | Online Article Text |
id | pubmed-9313204 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93132042022-07-26 Biomaterial-Mediated Factor Delivery for Spinal Cord Injury Treatment Pinelli, Filippo Pizzetti, Fabio Veneruso, Valeria Petillo, Emilia Raghunath, Michael Perale, Giuseppe Veglianese, Pietro Rossi, Filippo Biomedicines Review Spinal cord injury (SCI) is an injurious process that begins with immediate physical damage to the spinal cord and associated tissues during an acute traumatic event. However, the tissue damage expands in both intensity and volume in the subsequent subacute phase. At this stage, numerous events exacerbate the pathological condition, and therein lies the main cause of post-traumatic neural degeneration, which then ends with the chronic phase. In recent years, therapeutic interventions addressing different neurodegenerative mechanisms have been proposed, but have met with limited success when translated into clinical settings. The underlying reasons for this are that the pathogenesis of SCI is a continued multifactorial disease, and the treatment of only one factor is not sufficient to curb neural degeneration and resulting paralysis. Recent advances have led to the development of biomaterials aiming to promote in situ combinatorial strategies using drugs/biomolecules to achieve a maximized multitarget approach. This review provides an overview of single and combinatorial regenerative-factor-based treatments as well as potential delivery options to treat SCIs. MDPI 2022-07-12 /pmc/articles/PMC9313204/ /pubmed/35884981 http://dx.doi.org/10.3390/biomedicines10071673 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Pinelli, Filippo Pizzetti, Fabio Veneruso, Valeria Petillo, Emilia Raghunath, Michael Perale, Giuseppe Veglianese, Pietro Rossi, Filippo Biomaterial-Mediated Factor Delivery for Spinal Cord Injury Treatment |
title | Biomaterial-Mediated Factor Delivery for Spinal Cord Injury Treatment |
title_full | Biomaterial-Mediated Factor Delivery for Spinal Cord Injury Treatment |
title_fullStr | Biomaterial-Mediated Factor Delivery for Spinal Cord Injury Treatment |
title_full_unstemmed | Biomaterial-Mediated Factor Delivery for Spinal Cord Injury Treatment |
title_short | Biomaterial-Mediated Factor Delivery for Spinal Cord Injury Treatment |
title_sort | biomaterial-mediated factor delivery for spinal cord injury treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313204/ https://www.ncbi.nlm.nih.gov/pubmed/35884981 http://dx.doi.org/10.3390/biomedicines10071673 |
work_keys_str_mv | AT pinellifilippo biomaterialmediatedfactordeliveryforspinalcordinjurytreatment AT pizzettifabio biomaterialmediatedfactordeliveryforspinalcordinjurytreatment AT venerusovaleria biomaterialmediatedfactordeliveryforspinalcordinjurytreatment AT petilloemilia biomaterialmediatedfactordeliveryforspinalcordinjurytreatment AT raghunathmichael biomaterialmediatedfactordeliveryforspinalcordinjurytreatment AT peralegiuseppe biomaterialmediatedfactordeliveryforspinalcordinjurytreatment AT veglianesepietro biomaterialmediatedfactordeliveryforspinalcordinjurytreatment AT rossifilippo biomaterialmediatedfactordeliveryforspinalcordinjurytreatment |